These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32678313)

  • 21. Exosomal long non-coding RNA MSTRG.292666.16 is associated with osimertinib (AZD9291) resistance in non-small cell lung cancer.
    Deng Q; Fang Q; Xie B; Sun H; Bao Y; Zhou S
    Aging (Albany NY); 2020 May; 12(9):8001-8015. PubMed ID: 32375124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
    Xu J; Zhao X; He D; Wang J; Li W; Liu Y; Ma L; Jiang M; Teng Y; Wang Z; Gu M; Wu J; Wang Y; Yue W; Zhang S
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1413-1422. PubMed ID: 29797219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
    Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).
    Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
    Thorac Cancer; 2020 Sep; 11(9):2389-2397. PubMed ID: 32677256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer.
    Manabe T; Yasuda H; Terai H; Kagiwada H; Hamamoto J; Ebisudani T; Kobayashi K; Masuzawa K; Ikemura S; Kawada I; Hayashi Y; Fukui K; Horimoto K; Fukunaga K; Soejima K
    Mol Cancer Res; 2020 Apr; 18(4):549-559. PubMed ID: 31941753
    [No Abstract]   [Full Text] [Related]  

  • 26. [Activation of nuclear factor-κB subunit p50/p65 enhances gefitinib resistance of lung adenocarcinoma H1650 cell line].
    Pan Y; Huang SC; Wang X; Gong WX; Liang CW; DU JX; Peng DX; Xie Y; Zheng LP; Zhang N; Quan W
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 May; 38(5):584-590. PubMed ID: 29891456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.
    Yochum ZA; Cades J; Wang H; Chatterjee S; Simons BW; O'Brien JP; Khetarpal SK; Lemtiri-Chlieh G; Myers KV; Huang EH; Rudin CM; Tran PT; Burns TF
    Oncogene; 2019 Jan; 38(5):656-670. PubMed ID: 30171258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Novel Molecular Target in
    Takano N; Seike M; Sugano T; Matsuda K; Hisakane K; Yoshikawa A; Nakamichi S; Noro R; Gemma A
    Anticancer Res; 2022 Feb; 42(2):709-722. PubMed ID: 35093869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The role and mechanism of 2-deoxyglucose in reversing osimertinib-acquired resistance of non-small cell lung cancer cell line].
    Hao S; Lu CH; Lin CC; Chen HY; Li L; Wang YB; Feng MX; He Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Mar; 42(3):198-205. PubMed ID: 30845397
    [No Abstract]   [Full Text] [Related]  

  • 30. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mechanism of PLOD2 induced osimertinib resistance in non-small cell lung cancer HCC827 cells].
    Kang XH; Wang K; Wang Y; Zhao HK; Zhang J; Zhao KL; Miao ZH; Xu ZY; Cao F; Gong YB
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):210-215. PubMed ID: 32252199
    [No Abstract]   [Full Text] [Related]  

  • 32. Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations.
    Ohara S; Suda K; Mitsudomi T
    Cells; 2021 Feb; 10(2):. PubMed ID: 33572269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced EGF receptor-signaling potentiates TGFβ-induced lens epithelial-mesenchymal transition.
    Shu DY; Lovicu FJ
    Exp Eye Res; 2019 Aug; 185():107693. PubMed ID: 31201806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
    Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TGF-β promote epithelial-mesenchymal transition via NF-κB/NOX4/ROS signal pathway in lung cancer cells.
    Ma M; Shi F; Zhai R; Wang H; Li K; Xu C; Yao W; Zhou F
    Mol Biol Rep; 2021 Mar; 48(3):2365-2375. PubMed ID: 33792826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
    Wang J; Wei H; Zhao B; Li M; Lv W; Lv L; Song B; Lv S
    J Mol Histol; 2014 Dec; 45(6):641-52. PubMed ID: 25008024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caged-xanthone from Cratoxylum formosum ssp. pruniflorum inhibits malignant cancer phenotypes in multidrug-resistant human A549 lung cancer cells through down-regulation of NF-κB.
    Kaewpiboon C; Boonnak N; Yawut N; Kaowinn S; Chung YH
    Bioorg Med Chem; 2019 Jun; 27(12):2368-2375. PubMed ID: 30606669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance
    Starrett JH; Guernet AA; Cuomo ME; Poels KE; van Alderwerelt van Rosenburgh IK; Nagelberg A; Farnsworth D; Price KS; Khan H; Ashtekar KD; Gaefele M; Ayeni D; Stewart TF; Kuhlmann A; Kaech SM; Unni AM; Homer R; Lockwood WW; Michor F; Goldberg SB; Lemmon MA; Smith PD; Cross DAE; Politi K
    Cancer Res; 2020 May; 80(10):2017-2030. PubMed ID: 32193290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.